^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ilorasertib (ABT348)

    i
    Other names: ABT348, Abbott-968660, A-968660.0, ABT-348, ABT 348
    Associations

    News

    Trials
    Company:
    AbbVie
    Drug class:
    VEGFR inhibitor, PDGFR inhibitor, Aurora kinase inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors (clinicaltrials.gov)
    P2, N=12, Terminated, M.D. Anderson Cancer Center | Completed --> Terminated; Study terminated due to company's decision to discontinue drug development
    Trial termination • Pan tumor • Metastases
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A deletion • CDKN2A mutation
    |
    ilorasertib (ABT348)
    over2years
    Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors (clinicaltrials.gov)
    P2, N=12, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
    Trial completion • Pan tumor
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A deletion • CDKN2A mutation
    |
    ilorasertib (ABT348)